CompletedPHASE1, PHASE2NCT00068250
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Jon Glass, MDSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Intervention
- rituximab(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2016
Study locations (26)
- Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
- Integrated Community Oncology Network at Southside Cancer Center, Jacksonville, Florida, United States
- Baptist Medical Center South, Jacksonville, Florida, United States
- Integrated Community Oncology Network, Jacksonville Beach, Florida, United States
- Integrated Community Oncology Network - Orange Park, Orange Park, Florida, United States
- Florida Cancer Center - Palatka, Palatka, Florida, United States
- Flagler Cancer Center, Saint Augustine, Florida, United States
- Borgess Medical Center, Kalamazoo, Michigan, United States
- West Michigan Cancer Center, Kalamazoo, Michigan, United States
- Bronson Methodist Hospital, Kalamazoo, Michigan, United States
- CCOP - Kansas City, Kansas City, Missouri, United States
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
- CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
- John F. Kennedy Medical Center, Edison, New Jersey, United States
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00068250 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation
- RECRUITINGPHASE1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center
See all trials for Primary central nervous system lymphoma →